Transparencia en la investigación biomédica: A propósito de los riesgos asociados al uso de Avandia

The question of how and when to communicate potential risks associated with new drugs has remained an important focus of tension between the pharmaceutical industry and regulatory entities, such as the American Food and Drug Administration. Recently there has been widespread concern related to the c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	SALAS,SOFÍA P, RUSSO,MOISÉS
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2010
Materias:	Biomedical research Conflicts of interest Rosiglitazone
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872010000900017
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872010000900017
record_format	dspace
spelling	oai:scielo:S0034-988720100009000172010-11-09Transparencia en la investigación biomédica: A propósito de los riesgos asociados al uso de AvandiaSALAS,SOFÍA PRUSSO,MOISÉS Biomedical research Conflicts of interest Rosiglitazone The question of how and when to communicate potential risks associated with new drugs has remained an important focus of tension between the pharmaceutical industry and regulatory entities, such as the American Food and Drug Administration. Recently there has been widespread concern related to the cardiovascular risks associated with the use of Avandia, a rosiglitazone produced by Glaxo Smith Kline. In fact, several metaanalyses involving rosiglitazone provided a relatively consistent message that rosiglitazone increases the risk of myocardial ischemic events. In the present article, we review the controversy regarding the way the pharmaceutical company handled this issue, and we describe examples of inappropriate conduct regarding an industry-sponsored clinical trial with this drug. We raise several important ethical questions related to the way researchers handle conflicts of interest when they are employees of the pharmaceutical industry. Finally, we discuss the requirements to conduct biomedical research funded by the pharmaceutical industry in Chile.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.138 n.9 20102010-09-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872010000900017es10.4067/S0034-98872010000900017
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Biomedical research Conflicts of interest Rosiglitazone
spellingShingle	Biomedical research Conflicts of interest Rosiglitazone SALAS,SOFÍA P RUSSO,MOISÉS Transparencia en la investigación biomédica: A propósito de los riesgos asociados al uso de Avandia
description	The question of how and when to communicate potential risks associated with new drugs has remained an important focus of tension between the pharmaceutical industry and regulatory entities, such as the American Food and Drug Administration. Recently there has been widespread concern related to the cardiovascular risks associated with the use of Avandia, a rosiglitazone produced by Glaxo Smith Kline. In fact, several metaanalyses involving rosiglitazone provided a relatively consistent message that rosiglitazone increases the risk of myocardial ischemic events. In the present article, we review the controversy regarding the way the pharmaceutical company handled this issue, and we describe examples of inappropriate conduct regarding an industry-sponsored clinical trial with this drug. We raise several important ethical questions related to the way researchers handle conflicts of interest when they are employees of the pharmaceutical industry. Finally, we discuss the requirements to conduct biomedical research funded by the pharmaceutical industry in Chile.
author	SALAS,SOFÍA P RUSSO,MOISÉS
author_facet	SALAS,SOFÍA P RUSSO,MOISÉS
author_sort	SALAS,SOFÍA P
title	Transparencia en la investigación biomédica: A propósito de los riesgos asociados al uso de Avandia
title_short	Transparencia en la investigación biomédica: A propósito de los riesgos asociados al uso de Avandia
title_full	Transparencia en la investigación biomédica: A propósito de los riesgos asociados al uso de Avandia
title_fullStr	Transparencia en la investigación biomédica: A propósito de los riesgos asociados al uso de Avandia
title_full_unstemmed	Transparencia en la investigación biomédica: A propósito de los riesgos asociados al uso de Avandia
title_sort	transparencia en la investigación biomédica: a propósito de los riesgos asociados al uso de avandia
publisher	Sociedad Médica de Santiago
publishDate	2010
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872010000900017
work_keys_str_mv	AT salassofiap transparenciaenlainvestigacionbiomedicaapropositodelosriesgosasociadosalusodeavandia AT russomoises transparenciaenlainvestigacionbiomedicaapropositodelosriesgosasociadosalusodeavandia
_version_	1718436527639363585

Transparencia en la investigación biomédica: A propósito de los riesgos asociados al uso de Avandia

Ejemplares similares